Contribute Try STAT+ Today

Fibrogen was expecting the Food and Drug Administration to complete a review of its experimental anemia pill and render an approval decision by March 20. But in a surprising — and concerning — move announced Monday evening, the FDA has instead decided to convene a meeting of outside experts to review the drug’s clinical data.

The scheduling of the advisory panel this late in the review process is unusual and will delay the approval of the oral drug, called roxadustat, Fibrogen said Monday.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Drug is working well in Asia Why cant we approve it here. Anemia in CKD is diffcult and responds to Roxedustat

Comments are closed.